Abstract
During normal B-lymphocyte development once cells pass the pro-B stage the transcription factor LEF-1, a key component of the Wnt/beta-catenin pathway, is down regulated. However studies have shown that B-cell chronic lymphocytic leukaemia (CLL) lymphocytes, which have a mature B-cell phenotype, still express abundant LEF-1. This study demonstrates that although LEF-1 mRNA is universally, highly expressed in B-CLL, expression of this gene is much lower or absent in the majority of low-grade B-cell non-Hodgkin's lymphoma (NHL). This suggests that there exist key differences in the activity of the Wnt/beta-catenin pathway between low-grade B-cell malignancies.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
B-Lymphocytes / metabolism
-
B-Lymphocytes / pathology
-
Down-Regulation*
-
Female
-
Gene Expression Regulation, Leukemic*
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
-
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
-
Lymphoid Enhancer-Binding Factor 1 / biosynthesis*
-
Lymphoid Enhancer-Binding Factor 1 / genetics
-
Lymphoma, Non-Hodgkin / genetics
-
Lymphoma, Non-Hodgkin / metabolism*
-
Lymphoma, Non-Hodgkin / pathology
-
Male
-
Neoplasm Proteins / biosynthesis*
-
RNA, Messenger / biosynthesis
-
RNA, Messenger / genetics
-
Signal Transduction
-
Wnt Proteins / metabolism
-
beta Catenin / metabolism
Substances
-
Lymphoid Enhancer-Binding Factor 1
-
Neoplasm Proteins
-
RNA, Messenger
-
Wnt Proteins
-
beta Catenin